AZD 5396
Alternative Names: AZD-5396Latest Information Update: 23 Jun 2022
At a glance
- Originator Inovio Pharmaceuticals
- Class Antivirals; COVID-19 vaccines; DNA; DNA vaccines; Monoclonal antibodies; Synthetic vaccines
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 20 Jun 2022 AstraZeneca, Inovio Pharmaceuticals, Indiana University, University of Pennsylvania, and the Wistar Institute enters into RnD agreement for development of DNA encoded monoclonal antibodies
- 14 Jun 2022 Phase-I clinical trials in COVID-2019 infections (In the elderly, Prevention, In adults) in USA (IM) (NCT05293249)
- 09 Jun 2022 Preclinical clinical trials in COVID-2019 infections in USA (IM)